|Page (1) of 1 - 06/13/18||email article||print page|
Assembly Biosciences to Host Research and Development Day on Wednesday, June 20, 2018(June 13, 2018)
Live event and webcast to focus on the potential of curative therapy for HBV infection and feature presentations from two liver medicine specialists
INDIANAPOLIS and SAN FRANCISCO, June 13, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel oral synthetic live biotherapeutics for disorders associated with the microbiome, today announced that it plans to host a Research and Development Day including a live audio webcast on Wednesday, June 20, 2018, at 11:30 am ET.
Company management will present the scientific rationale for core inhibitors to become a potential backbone to a curative regimen for patients with chronic HBV, the limitations of current standard-of-care for chronic HBV, Assembly’s clinical results and development plans for its core inhibitor candidates, and the potential impact of curative therapy on HBV market dynamics.
Epidemiology of the disease, medical need and strategies for improving cure rates will be discussed by two physician guest speakers:
- Douglas T. Dieterich, MD—Director, Institute of Liver Medicine, Professor of Medicine, Division of Liver Disease, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY.
- Jörg Petersen, MD, PhD —Professor of Medicine and Head of the Liver Unit at the IFI Institute for Interdisciplinary Medicine at the Asklepios Klinik St. George, University of Hamburg, Germany.
The live audio webcast may be accessed through the "Events & Presentations" page in the "Investors" section of the company's website at assemblybio.com. The archived webcast will be available on Assembly’s website beginning approximately two hours after the event and will be archived and available for replay for at least 30 days after the event.
Institutional investors and equity analysts seeking information or registration for the live event in New York City may refer to the contact information within this press release.
About Assembly Biosciences
Assembly Biosciences, Inc. is a clinical-stage public biotechnology company developing two innovative platform programs: an HBV program advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and a microbiome program developing novel oral live biotherapeutics designed to address diseases associated with the microbiome. Assembly’s HBV program is advancing multiple drug candidates with the aim of increasing cure rates in patients with chronic HBV. The company's microbiome program consists of a fully integrated platform that includes a robust strain identification and selection process, methods for strain isolation and growth under current Good Manufacturing Practices and a patented delivery system, GEMICEL®, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal tract. Assembly is developing a robust pipeline of product candidates in multiple disease indications. For more information, visit assemblybio.com.
The information in this press release contains forward-looking statements regarding future events, including statements about the clinical and therapeutic potential of core inhibitors, including ABI-H0731, and the timing of Assembly’s planned clinical studies. Certain forward-looking statements may be identified by reference to a future period or by use of forward-looking terminology such as “will,” “expected,” and “potential.” Assembly intends such forward-looking statements to be covered by the safe harbor provisions contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. More information about the risks and uncertainties faced by Assembly are more fully detailed under the heading “Risk Factors” in Assembly’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2018 filed with the Securities and Exchange Commission. Except as required by law, Assembly assumes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
Assembly Biosciences, Inc.